FDA issues warning on 4 widely-used asthma drugs

Feb 18, 2010 By LAURAN NEERGAARD , AP Medical Writer

(AP) -- The government is issuing new restrictions on some widely used long-acting asthma drugs, saying they should never be used without other asthma controllers to prevent a lifethreatening risk.

Four medications - Foradil, Serevent, Advair and Symbicort - contain an ingredient that relaxes muscles in the lung's airways. While they're very helpful for some patients, the way they work also may mask symptoms that can trigger serious attacks. It's a particular concern for children.

The ordered new labels saying the drugs should be used for the shortest possible duration - and only together with other medications such as inhaled steroids that work differently, by relieving airway inflammation.

Explore further: Most US babies get their vaccines, CDC says

5 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Asthma risk increases in children treated for HIV

Jul 01, 2008

Children whose immune systems rebound after treatment with potent anti-viral drugs for HIV infection face an increased risk of developing asthma, said a federally funded consortium of researchers led by those from Baylor ...

More pounds equals worse asthma?

May 22, 2007

A new study presented at the American Thoracic Society 2007 International Conference finds that obese people are significantly more likely to have persistent or severe persistent asthma than their thinner counterparts.

Recommended for you

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

Expression of privilege in vaccine refusal

Aug 27, 2014

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

User comments : 0